TLR4 predicts patient prognosis and immunotherapy efficacy in clear cell renal cell carcinoma

Background: Clear cell renal cell carcinoma (ccRCC) constitutes the commonest kidney malignancy. Immunogenic cell death (ICD) is a type of regulated cell death (RCD), which sufficiently activates adaptive immunity. However, ICD's involvement in cancer development is unclear, as well as the associations of ICD effectors with ccRCC prognosis. Methods: RNA-sequencing expression profiles of ccRCC in The Cancer Genome Atlas (TCGA) and normal samples in Gene Expression Omnibus (GEO) were comprehensively investigated. Consensus clustering analysis was employed to determine subgroup members linked to ICD-related genes. Functional enrichment analysis was utilized for the examination of TLR4's biological role, and in vitro cellular assays were utilized for further confirmation. We also used Kaplan-Meier (KM) and Cox regression analyses to assess TLR4's prognostic value. Finally, “CIBERSORT” was employed for immune score evaluation. Results: The associations of ICD effectors with ccRCC prognosis were examined based on TCGA, and 12 genes showed upregulation in ccRCC tissue specimens. Meanwhile, ccRCC cases with upregulated ICD-related genes had increased overall survival. Among these ICD-related genes, TLR4 was selected for subsequent analysis. TLR4 was upregulated in ccRCC samples and independently predicted ccRCC. TLR4 also enhanced the proliferative, migratory and invasive abilities in cultured ccRCC cells. Moreover, TLR4 had close relationships with immune checkpoints and infiltrated immune cells. ccRCC cases with elevated TLR4 expression had prolonged overall survival, suggesting a prognostic value for TLR4. Finally, a pan-cancer analysis demonstrated TLR4 had differential expression in various malignancies in comparison with normal tissue samples. Conclusions: This study revealed prognostic values for ICD-associated genes, particularly TLR4, and experimentally validated the inducing effects of TLR4 on ccRCC progression in vitro. We also demonstrated the associations of TLR4 with immune cell infiltration, providing a novel strategy for prognostic evaluation and a novel therapeutic target in ccRCC.

[1]  Jeong Hun Kim,et al.  Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade , 2022, Journal for ImmunoTherapy of Cancer.

[2]  S. Mustjoki,et al.  T and NK cell abundance defines two distinct subgroups of renal cell carcinoma , 2022, Oncoimmunology.

[3]  Wenchuan Wu,et al.  Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer , 2021, Cell Death & Disease.

[4]  Na Li,et al.  Immunogenic cell death inducers for enhanced cancer immunotherapy. , 2021, Chemical communications.

[5]  Jie Guo,et al.  TLR4 signaling in the development of colitis-associated cancer and its possible interplay with microRNA-155 , 2021, Cell communication and signaling : CCS.

[6]  Minghua Wu,et al.  Pattern recognition receptors in health and diseases , 2021, Signal Transduction and Targeted Therapy.

[7]  X. Cui,et al.  FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity , 2021, BMC Cancer.

[8]  Jimmy P. Xu,et al.  Cholesterol auxotrophy as a targetable vulnerability in clear cell renal cell carcinoma. , 2021, Cancer discovery.

[9]  P. Hegde,et al.  Molecular determinants of response to PD-L1 blockade across tumor types , 2021, Nature Communications.

[10]  Jiayi Ji,et al.  New frontiers against sorafenib resistance in renal cell carcinoma: from molecular mechanisms to predictive biomarkers. , 2021, Pharmacological research.

[11]  Jing Ning,et al.  Oleandrin, a cardiac glycoside, induces immunogenic cell death via the PERK/elF2α/ATF4/CHOP pathway in breast cancer , 2021, Cell Death & Disease.

[12]  Steven L. Chang,et al.  Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma , 2021, Cancer cell.

[13]  X. Ren,et al.  Morphine-3-glucuronide upregulates PD-L1 expression via TLR4 and promotes the immune escape of non-small cell lung cancer , 2021, Cancer biology & medicine.

[14]  J. López,et al.  Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma , 2021, Cancers.

[15]  M. Baldewijns,et al.  C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab. , 2021, Urologic oncology.

[16]  N. Sun,et al.  Survival Nomogram for Stage IB Non-Small-Cell Lung Cancer Patients, Based on the SEER Database and an External Validation Cohort , 2020, Annals of Surgical Oncology.

[17]  Asma Ahmed,et al.  Targeting immunogenic cell death in cancer , 2020, Molecular oncology.

[18]  L. Galluzzi,et al.  Detection of immunogenic cell death and its relevance for cancer therapy , 2020, Cell Death & Disease.

[19]  P. Hegde,et al.  Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. , 2020, Cancer cell.

[20]  Matthew C L Phillips,et al.  Epithelial TLR4 signaling activates DUOX2 to induce microbiota-driven tumorigenesis. , 2020, Gastroenterology.

[21]  Bikash R. Sahoo.  Structure of fish Toll-like receptors (TLR) and NOD-like receptors (NLR) , 2020, International Journal of Biological Macromolecules.

[22]  Til Stürmer,et al.  Real-world evidence: the devil is in the detail , 2020, Diabetologia.

[23]  S. Chattopadhyay,et al.  Insight Into TLR4-Mediated Immunomodulation in Normal Pregnancy and Related Disorders , 2020, Frontiers in Immunology.

[24]  I. McNeish,et al.  Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE-Dependent Exocytosis , 2020, Cancer Immunology Research.

[25]  F. Marincola,et al.  Consensus guidelines for the definition, detection and interpretation of immunogenic cell death , 2020, Journal for ImmunoTherapy of Cancer.

[26]  J. Balko,et al.  Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma , 2020, Journal for ImmunoTherapy of Cancer.

[27]  Min Li,et al.  Acylglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3β signalling pathway in renal cell carcinoma , 2020, Journal of Hematology & Oncology.

[28]  Ran-yi Liu,et al.  HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma , 2020, Journal for ImmunoTherapy of Cancer.

[29]  Maxim N. Artyomov,et al.  MHC-II neoantigens shape tumor immunity and response to immunotherapy , 2019, Nature.

[30]  Yan Yan,et al.  Hyaluronic Acid Binding to TLR4 Promotes Proliferation and Blocks Apoptosis in Colon Cancer , 2019, Molecular Cancer Therapeutics.

[31]  I. Melero,et al.  Dendritic cells in cancer immunology and immunotherapy , 2019, Nature Reviews Immunology.

[32]  Xuetao Cao,et al.  Nuclear hnRNPA2B1 initiates and amplifies the innate immune response to DNA viruses , 2019, Science.

[33]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[34]  C. Pathak,et al.  Human Toll-Like Receptor 4 (hTLR4): Structural and functional dynamics in cancer. , 2019, International journal of biological macromolecules.

[35]  A. Lamprecht,et al.  TLR4-Based Immunotherapeutics in Cancer: A Review of the Achievements and Shortcomings. , 2018, Molecular pharmaceutics.

[36]  Chi-Ming Liu,et al.  The Cancer Prevention, Anti-Inflammatory and Anti-Oxidation of Bioactive Phytochemicals Targeting the TLR4 Signaling Pathway , 2018, International journal of molecular sciences.

[37]  M. Hou,et al.  Resistin facilitates breast cancer progression via TLR4-mediated induction of mesenchymal phenotypes and stemness properties , 2018, Oncogene.

[38]  B. Rini,et al.  Treatment of renal cell carcinoma: Current status and future directions , 2017, CA: a cancer journal for clinicians.

[39]  C. Caux,et al.  Pattern recognition receptors: immune targets to enhance cancer immunotherapy , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  R. Weiss,et al.  Metabolic reprogramming in clear cell renal cell carcinoma , 2017, Nature Reviews Nephrology.

[41]  D. de Ruysscher,et al.  Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: A large-scale meta-analysis , 2016, Oncoimmunology.

[42]  G. Mills,et al.  The PI3K/AKT Pathway and Renal Cell Carcinoma. , 2015, Journal of genetics and genomics = Yi chuan xue bao.

[43]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[44]  Nan Li,et al.  TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells , 2013, Cellular and Molecular Immunology.

[45]  L. Zitvogel,et al.  Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists , 2013, Cell Death and Differentiation.

[46]  P. Vandenabeele,et al.  ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death , 2013, Autophagy.

[47]  L. Zitvogel,et al.  Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death , 2012, Autophagy.

[48]  Yukio Fujiwara,et al.  Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma , 2011, Cancer science.

[49]  J. Knottnerus,et al.  Real world research. , 2010, Journal of clinical epidemiology.

[50]  Matthew D. Wilkerson,et al.  ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..

[51]  Hayyoung Lee,et al.  The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex , 2009, Nature.

[52]  K. Leśniewski-Kmak,et al.  Immunology of renal cell carcinoma , 2007 .